Navigation Links
Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
Date:9/27/2007

Barcelona, Spain: Giving pancreatic cancer patients the chemotherapy drug gemcitabine after surgery delays progression of the disease by about six months, according to new research by Japanese scientists.

The study, presented today (Thursday) at the European Cancer Conference (ECCO 14) in Barcelona, found that the drug more than doubled the average disease-free survival from 4.9 months to 11.4 months.

We believe that a median disease-free survival of 11.4 months is an outstanding result. It means an improvement, or reduction in the risk of recurrence, of 41 percent, said the studys lead researcher, Dr Tomoo Kosuge, deputy director of the National Cancer Center Hospital in Tokyo, Japan. That is difficult to achieve in patients with pancreatic cancer.

Pancreatic cancer has among the poorest prognoses. Most often, it has already spread by the time it is diagnosed, but in about 20 percent of patients, surgery is a viable option. However, even if it can be operated on, the cancer normally recurs and more than half of patients die within 20 months of their diagnosis. Only around 20 percent of them are still alive five years after being diagnosed.

Chemotherapy with gemcitabine is the standard treatment for advanced pancreatic cancer that cannot be operated on. As for resectable pancreatic cancer, researchers are investigating whether chemotherapy or chemoradiation might help. However, there is no universally accepted adjuvant treatment for patients whose pancreas can be removed, so mere observation after surgery is still the widely accepted approach.

In the latest study, 118 patients whose pancreatic cancer could be cut out were either given gemcitabine chemotherapy after surgery or closely monitored by doctors. Both groups were followed for more than 20 months.

The disease recurred in 72 percent of the patients getting gemcitabine, compared with 85 percent of those on observation. The overall survival, meaning survival regardless of whether the disease progressed, was better in the gemcitabine group, but those results were not statistically significant.

In the results of our study, the lack of a significant difference in the overall survival means the observation approach was not altogether negated. We therefore propose that chemotherapy with gemcitabine, as well as observation, now be considered as optimal treatment for patients with operable pancreatic cancer, Kosuge said.

The Japanese study bolsters the findings of a German study published earlier this year that similarly found gemcitabine delays progression of the disease after surgery.


'/>"/>

Contact: Emma Ross
rosswrite@mac.com
34-932-308-832
ECCO-the European CanCer Conference
Source:Eurekalert

Related medicine news :

1. Acupuncture May Help Chemotherapy Side Effects
2. Chemotherapy Pill Has Fewer Side Effects Than IV
3. Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"
4. Response to chemotherapy could be measured by Prostate-Specific Antigen Doubling Time
5. Therapy Boosts Chemotherapy Effects
6. Chemotherapy Effective for Bladder Cancer
7. New Method Of Delivering Chemotherapy
8. The Benefits Of Chemotherapy For Women With Ovarian Cancer
9. New Compound Could Strengthen The Effect Of Chemotherapy
10. Older Breast Cancer Patients Can Be Effectively Treated With Chemotherapy
11. Using herbal remedies with chemotherapy may not be a good idea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
(Date:6/23/2016)... , June 23, 2016 Revolutionary ... Oticon , industry leaders in advanced audiology ... of Oticon Opn ™, the world,s first internet ... possibilities for IoT devices.      (Photo: ... introduces a number of ,world firsts,: , ...
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
Breaking Medicine Technology: